首页 > 最新文献

Therapie最新文献

英文 中文
How can the reform of the activity-based payment system (T2A) help in financing innovative health products? 基于活动的支付系统(T2A)的改革如何有助于创新卫生产品的融资?
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1016/j.therap.2024.10.063
Xavier Armoiry , Nejma Saidani , Martine Aoustin , Dorothée Camus , Auriane Cano-Chancel , Sophie Carlier , Albane Degrassat-Théas , Anne-Aurélie Epis de Fleurian , Anne Grumblat , Aurélie Lavorel , Mégane Lesaignoux , Tess Martin , Adrien Michaud , Jonathan Morizot , Nathalie Préaubert , Valery-Pierre Riche , Isabelle Durand Zaleski
In France, the short-stay activities of public and private sector healthcare facilities have been financed since 2004 by activity-based pricing (T2A). The principle is to allow for payment determined primarily by the nature and volume of activities. T2A has enabled a major transformation compared to the old financing system, chiefly for public sector facilities that used to operate under a general allocation, and convergence between payment methods in the public and private sectors. However, official reports and public pronouncements by many hospital healthcare stakeholders have also highlighted the limits of this method of financing, leading to several reform projects. With that in mind, round table 3 of the Giens Workshops, including experts from academia and/or hospitals, institutions, and industry, questioned the impact of the new T2A reforms on access to innovative health care products in hospitals. After scoping out the issue and drawing up observations, the round table proposed six general recommendations that would be avenues for improving access to innovative health care products for hospital service users.
在法国,自2004年以来,公共和私营部门保健设施的短期住院活动一直采用基于活动的定价方式(T2A)。其原则是允许主要由活动的性质和数量决定的付款。与旧的融资体系相比,T2A实现了重大转变,主要是针对过去在一般拨款下运作的公共部门设施,以及公共和私营部门支付方式的融合。然而,许多医院医疗保健利益相关者的官方报告和公开声明也强调了这种融资方式的局限性,导致了几个改革项目。考虑到这一点,包括来自学术界和(或)医院、机构和产业界的专家在内的Giens讲习班圆桌会议3对T2A新改革对医院获得创新医疗保健产品的影响提出了质疑。在确定问题范围并提出意见之后,圆桌会议提出了六项一般性建议,这些建议将成为改善医院服务使用者获得创新保健产品的途径。
{"title":"How can the reform of the activity-based payment system (T2A) help in financing innovative health products?","authors":"Xavier Armoiry ,&nbsp;Nejma Saidani ,&nbsp;Martine Aoustin ,&nbsp;Dorothée Camus ,&nbsp;Auriane Cano-Chancel ,&nbsp;Sophie Carlier ,&nbsp;Albane Degrassat-Théas ,&nbsp;Anne-Aurélie Epis de Fleurian ,&nbsp;Anne Grumblat ,&nbsp;Aurélie Lavorel ,&nbsp;Mégane Lesaignoux ,&nbsp;Tess Martin ,&nbsp;Adrien Michaud ,&nbsp;Jonathan Morizot ,&nbsp;Nathalie Préaubert ,&nbsp;Valery-Pierre Riche ,&nbsp;Isabelle Durand Zaleski","doi":"10.1016/j.therap.2024.10.063","DOIUrl":"10.1016/j.therap.2024.10.063","url":null,"abstract":"<div><div>In France, the short-stay activities of public and private sector healthcare facilities have been financed since 2004 by activity-based pricing (T2A). The principle is to allow for payment determined primarily by the nature and volume of activities. T2A has enabled a major transformation compared to the old financing system, chiefly for public sector facilities that used to operate under a general allocation, and convergence between payment methods in the public and private sectors. However, official reports and public pronouncements by many hospital healthcare stakeholders have also highlighted the limits of this method of financing, leading to several reform projects. With that in mind, round table 3 of the Giens Workshops, including experts from academia and/or hospitals, institutions, and industry, questioned the impact of the new T2A reforms on access to innovative health care products in hospitals. After scoping out the issue and drawing up observations, the round table proposed six general recommendations that would be avenues for improving access to innovative health care products for hospital service users.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 1","pages":"Pages 77-92"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health data: Regionalised access is a priority challenge for building a secure, transparent and innovative national health data repository 卫生数据:区域获取是建立安全、透明和创新的国家卫生数据存储库的一项优先挑战。
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1016/j.therap.2024.12.008
Daniel Szeftel , Vianney Jouhet , Gilles Duluc , Cécile Charle-Maachi , Thomas Sejourné , Jérôme Fabiano , Hélène Guimiot , Aurore Gaignon , Caroline Germain , Quentin Demanet , Emmanuel Merieux , Thomas Rapp
France has been engaged in a legal and organisational transition for many years. It has had to adapt its national framework to the legal requirements of personal data protection, European ambitions and international competition. From the Data Protection Act of 1978 to the Healthcare System Transformation Act of 2019, reforms have strengthened requirements in terms of personal data protection, while opening the way to innovative uses. Recent European regulations, such as the AI Act (2024) and the European Health Data Area (2024), aim to reinforce this dynamic, ensuring a secure, transparent and competitive framework for the sharing and use of health data. How can we ensure that the re-use of healthcare data is truly effective, while respecting the fundamental rights of citizens? How can we reconcile national and European ambitions with the technical and organisational realities of the healthcare system, in clinical and research teams, and as close as possible to patients and users in our territories? These questions are essential, because access to and use of health data are seen as major levers for improving the quality of care, supporting innovation and boosting the competitiveness of the French healthcare system. The impact study on the 2019 reform stresses that the transformation of the healthcare system will have to be based on taking better account of the needs of patients and professionals by encouraging local initiatives. In this context, France faces a priority to establish greater coordination between the national and local levels, while preserving the trust of users. This precious trust is essential if we are to make the transition to achieving national and European objectives for the scientific and economic use of data.
多年来,法国一直在进行法律和组织上的过渡。它不得不调整其国家框架,以适应个人数据保护的法律要求、欧洲的雄心和国际竞争。从1978年的《数据保护法》到2019年的《医疗体系转型法案》,改革加强了对个人数据保护的要求,同时为创新使用开辟了道路。最近的欧洲法规,如《人工智能法》(2024年)和《欧洲卫生数据区》(2024年),旨在加强这一动态,确保共享和使用卫生数据的安全、透明和有竞争力的框架。我们如何确保医疗数据的再利用真正有效,同时尊重公民的基本权利?我们如何使国家和欧洲的雄心与医疗保健系统、临床和研究团队的技术和组织现实,以及尽可能接近我们领土上的患者和用户协调起来?这些问题至关重要,因为卫生数据的获取和使用被视为提高医疗质量、支持创新和提高法国卫生保健系统竞争力的主要杠杆。对2019年改革的影响研究强调,医疗体系的转型必须建立在鼓励地方举措、更好地考虑患者和专业人员需求的基础上。在这方面,法国面临的一个优先事项是在国家和地方各级之间建立更大的协调,同时保持用户的信任。如果我们要过渡到实现国家和欧洲在科学和经济使用数据方面的目标,这种宝贵的信任是必不可少的。
{"title":"Health data: Regionalised access is a priority challenge for building a secure, transparent and innovative national health data repository","authors":"Daniel Szeftel ,&nbsp;Vianney Jouhet ,&nbsp;Gilles Duluc ,&nbsp;Cécile Charle-Maachi ,&nbsp;Thomas Sejourné ,&nbsp;Jérôme Fabiano ,&nbsp;Hélène Guimiot ,&nbsp;Aurore Gaignon ,&nbsp;Caroline Germain ,&nbsp;Quentin Demanet ,&nbsp;Emmanuel Merieux ,&nbsp;Thomas Rapp","doi":"10.1016/j.therap.2024.12.008","DOIUrl":"10.1016/j.therap.2024.12.008","url":null,"abstract":"<div><div>France has been engaged in a legal and organisational transition for many years. It has had to adapt its national framework to the legal requirements of personal data protection, European ambitions and international competition. From the Data Protection Act of 1978 to the Healthcare System Transformation Act of 2019, reforms have strengthened requirements in terms of personal data protection, while opening the way to innovative uses. Recent European regulations, such as the AI Act (2024) and the European Health Data Area (2024), aim to reinforce this dynamic, ensuring a secure, transparent and competitive framework for the sharing and use of health data. How can we ensure that the re-use of healthcare data is truly effective, while respecting the fundamental rights of citizens? How can we reconcile national and European ambitions with the technical and organisational realities of the healthcare system, in clinical and research teams, and as close as possible to patients and users in our territories? These questions are essential, because access to and use of health data are seen as major levers for improving the quality of care, supporting innovation and boosting the competitiveness of the French healthcare system. The impact study on the 2019 reform stresses that the transformation of the healthcare system will have to be based on taking better account of the needs of patients and professionals by encouraging local initiatives. In this context, France faces a priority to establish greater coordination between the national and local levels, while preserving the trust of users. This precious trust is essential if we are to make the transition to achieving national and European objectives for the scientific and economic use of data.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 1","pages":"Pages 125-134"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactic acidosis with metformin accumulation in the intensive care units of the Nord Pas de Calais region: A known serious adverse event that can be better prevented. 乳酸酸中毒与二甲双胍积累在北加来海峡地区的重症监护病房:一个已知的严重不良事件,可以更好地预防。
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-27 DOI: 10.1016/j.therap.2024.12.009
Sophie Gautier, Julie Truong-Minh, Johana Béné, Johanna Temime, Maxime Granier, Benjamin Hennart, Sandrine Bergeron, Emmanuelle Jaillette

Objective: Metformin-associated lactic acidosis (MALA) is a rare but serious adverse drug reaction (ADR). The aim of the study was to identify clinical situations associated with the onset of MALA in patients hospitalised in the Nord Pas de Calais regional intensive care units (ICUs), and to assess its preventability.

Material and methods: We included all cases of MALA, identified by metformin accumulation >2.3mg/dL and lactate >2.2mmol/L, reported by the regional ICU physicians to the Regional Centre of Pharmacovigilance and registered in the French Pharmacovigilance Database between 1 January 2017 and 30 December 2018.

Results: One hundred and ninety-eight (198) cases of MALA were included. 38 patients died in direct association with MALA (19.2%). There was a correlation between metformin plasma accumulation and acute renal failure and with the severity of MALA (P<0.0001). All patients presented an acute intercurrent event favouring MALA, dehydration for 87 (43.9%) patients, severe infection for 65 (32.8%) patients. For 172 patients (86.7%), the prescription was not adapted to the intercurrent medical situation as recommended. Seventy (40.5%) patients consulted their general practitioner for the acute intercurrent event, 1 temporarily stopped metformin and 34.3% had been referred directly to hospital. The remaining 65.7% presented to the hospital around 4 days later due to worsening symptoms. MALA was identified as preventable in 160 patients (80.8%).

Conclusions: MALA in ICUs often follow acute dehydration or infection, and these high-risk situations must be signals to prevent this serious ADR. Specific education programmes for physicians and patients could also reduce this risk.

目的:二甲双胍相关性乳酸性酸中毒(MALA)是一种罕见但严重的药物不良反应(ADR)。该研究的目的是确定在北加来海峡地区重症监护病房(icu)住院的患者中与MALA发病相关的临床情况,并评估其可预防性。材料和方法:我们纳入了2017年1月1日至2018年12月30日期间由地区ICU医生向区域药物警戒中心报告并在法国药物警戒数据库中登记的所有MALA病例,这些病例由二甲双胍积累>2.3mg/dL和乳酸>2.2mmol/L确定。结果:共纳入198例MALA。与MALA直接相关的死亡38例(19.2%)。二甲双胍血浆积存与急性肾功能衰竭及MALA严重程度存在相关性(p)结论:icu患者MALA常伴发急性脱水或感染,这些高危情况必须作为预防严重不良反应的信号。针对医生和患者的特殊教育项目也可以降低这种风险。
{"title":"Lactic acidosis with metformin accumulation in the intensive care units of the Nord Pas de Calais region: A known serious adverse event that can be better prevented.","authors":"Sophie Gautier, Julie Truong-Minh, Johana Béné, Johanna Temime, Maxime Granier, Benjamin Hennart, Sandrine Bergeron, Emmanuelle Jaillette","doi":"10.1016/j.therap.2024.12.009","DOIUrl":"https://doi.org/10.1016/j.therap.2024.12.009","url":null,"abstract":"<p><strong>Objective: </strong>Metformin-associated lactic acidosis (MALA) is a rare but serious adverse drug reaction (ADR). The aim of the study was to identify clinical situations associated with the onset of MALA in patients hospitalised in the Nord Pas de Calais regional intensive care units (ICUs), and to assess its preventability.</p><p><strong>Material and methods: </strong>We included all cases of MALA, identified by metformin accumulation >2.3mg/dL and lactate >2.2mmol/L, reported by the regional ICU physicians to the Regional Centre of Pharmacovigilance and registered in the French Pharmacovigilance Database between 1 January 2017 and 30 December 2018.</p><p><strong>Results: </strong>One hundred and ninety-eight (198) cases of MALA were included. 38 patients died in direct association with MALA (19.2%). There was a correlation between metformin plasma accumulation and acute renal failure and with the severity of MALA (P<0.0001). All patients presented an acute intercurrent event favouring MALA, dehydration for 87 (43.9%) patients, severe infection for 65 (32.8%) patients. For 172 patients (86.7%), the prescription was not adapted to the intercurrent medical situation as recommended. Seventy (40.5%) patients consulted their general practitioner for the acute intercurrent event, 1 temporarily stopped metformin and 34.3% had been referred directly to hospital. The remaining 65.7% presented to the hospital around 4 days later due to worsening symptoms. MALA was identified as preventable in 160 patients (80.8%).</p><p><strong>Conclusions: </strong>MALA in ICUs often follow acute dehydration or infection, and these high-risk situations must be signals to prevent this serious ADR. Specific education programmes for physicians and patients could also reduce this risk.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adalimumab-induced myoclonus: A potential adverse drug reaction? 阿达木单抗诱导的肌阵挛:潜在的药物不良反应?
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-17 DOI: 10.1016/j.therap.2024.12.006
Yasmine Salem Mahjoubi, Israa Dahmani, Fatma Zgolli, Widd Kaabi, Sarrah Kastalli, Imen Aouintin, Sihem El Aidli
{"title":"Adalimumab-induced myoclonus: A potential adverse drug reaction?","authors":"Yasmine Salem Mahjoubi, Israa Dahmani, Fatma Zgolli, Widd Kaabi, Sarrah Kastalli, Imen Aouintin, Sihem El Aidli","doi":"10.1016/j.therap.2024.12.006","DOIUrl":"https://doi.org/10.1016/j.therap.2024.12.006","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group. 塑造法国药物流行病学的未来:SFPT药物流行病学工作组的建议。
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-14 DOI: 10.1016/j.therap.2024.12.005
Thomas Soeiro, Marion Allouchery, Johana Bene, Julien Bezin, Charles Dolladille, Jean-Luc Faillie, Lamiae Grimaldi, Florentia Kaguelidou, Charles Khouri, Margaux Lafaurie, Bérenger Largeau, François Montastruc, Lucas Morin, Lucie-Marie Scailteux, Antoine Pariente

The drug authorization process is shifting towards a policy aimed at shortening time-to-market. While this policy facilitates early access to new treatments, it can also result in potentially insufficient knowledge of both efficacy and safety at the time of marketing. The latter is particularly true for long-term outcomes or in specific populations (e.g., children and the elderly). Yet, French pharmacoepidemiology is currently not designed to address these challenges, despite recognized expertise. In this context, we aim: (i) to define a strategy for strengthening pharmacoepidemiology in France; and (ii) to identify the associated human, technical, and financial requirements to ensure its success. In this paper, we present the French Pharmacoepidemiology Initiative (https://frenchpharmacoepi.org/), i.e. a network of independent academic teams to complement existing institutions. It will provide coordinated expertise and a workforce to meet national and regional needs for pharmacoepidemiological monitoring and drug-related decision-making. Leveraging the existing expertise of university hospital pharmacoepidemiology units would enable rapid operational deployment to inform the decisions and policies of national regulatory agencies.

药物授权程序正在转向旨在缩短上市时间的政策。虽然这一政策有助于尽早获得新疗法,但也可能导致在上市时对疗效和安全性的了解可能不足。对于长期结果或特定人群(如儿童和老年人)而言,后者尤其如此。然而,尽管有公认的专业知识,法国的药物流行病学目前还没有设计来应对这些挑战。在此背景下,我们的目标是:(i)确定加强法国药物流行病学的战略;(ii)确定相关的人力、技术和财务需求,以确保其成功。在本文中,我们介绍了法国药物流行病学倡议(https://frenchpharmacoepi.org/),即一个独立学术团队网络,以补充现有机构。它将提供协调一致的专门知识和工作人员,以满足国家和区域在药物流行病学监测和药物相关决策方面的需要。利用大学医院药物流行病学单位的现有专业知识,将能够快速开展业务部署,为国家监管机构的决策和政策提供信息。
{"title":"Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group.","authors":"Thomas Soeiro, Marion Allouchery, Johana Bene, Julien Bezin, Charles Dolladille, Jean-Luc Faillie, Lamiae Grimaldi, Florentia Kaguelidou, Charles Khouri, Margaux Lafaurie, Bérenger Largeau, François Montastruc, Lucas Morin, Lucie-Marie Scailteux, Antoine Pariente","doi":"10.1016/j.therap.2024.12.005","DOIUrl":"https://doi.org/10.1016/j.therap.2024.12.005","url":null,"abstract":"<p><p>The drug authorization process is shifting towards a policy aimed at shortening time-to-market. While this policy facilitates early access to new treatments, it can also result in potentially insufficient knowledge of both efficacy and safety at the time of marketing. The latter is particularly true for long-term outcomes or in specific populations (e.g., children and the elderly). Yet, French pharmacoepidemiology is currently not designed to address these challenges, despite recognized expertise. In this context, we aim: (i) to define a strategy for strengthening pharmacoepidemiology in France; and (ii) to identify the associated human, technical, and financial requirements to ensure its success. In this paper, we present the French Pharmacoepidemiology Initiative (https://frenchpharmacoepi.org/), i.e. a network of independent academic teams to complement existing institutions. It will provide coordinated expertise and a workforce to meet national and regional needs for pharmacoepidemiological monitoring and drug-related decision-making. Leveraging the existing expertise of university hospital pharmacoepidemiology units would enable rapid operational deployment to inform the decisions and policies of national regulatory agencies.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactulose induced maculo-papular eruption with positive rechallenge: Unusual reaction to this medication. 乳果糖诱导的斑疹丘疹阳性再挑战:对这种药物的不寻常反应。
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-11 DOI: 10.1016/j.therap.2024.12.004
Imen Bouaziz, Rim Atheymen, Khadija Sellami, Rym Sahnoun, Kamilia Ksouda, Emna Bahloul, Hanen Affes, Serria Hammami, Hamida Turki, Khaled Zghal
{"title":"Lactulose induced maculo-papular eruption with positive rechallenge: Unusual reaction to this medication.","authors":"Imen Bouaziz, Rim Atheymen, Khadija Sellami, Rym Sahnoun, Kamilia Ksouda, Emna Bahloul, Hanen Affes, Serria Hammami, Hamida Turki, Khaled Zghal","doi":"10.1016/j.therap.2024.12.004","DOIUrl":"https://doi.org/10.1016/j.therap.2024.12.004","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polyintoxication with cenobamate, perampanel, and carbamazepine: A complex case report. 多中毒与辛奥巴酸,perampanel和卡马西平:一个复杂的病例报告。
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-05 DOI: 10.1016/j.therap.2024.12.001
Alexandre Destere, Alexandre O Gérard, Diane Merino, Elliot Ewig, Fanny Rocher, Nouha Ben Othmann, Benjamin Hennart, Jean Dellamonica, Hervé Hyvernat, Milou-Daniel Drici
{"title":"Polyintoxication with cenobamate, perampanel, and carbamazepine: A complex case report.","authors":"Alexandre Destere, Alexandre O Gérard, Diane Merino, Elliot Ewig, Fanny Rocher, Nouha Ben Othmann, Benjamin Hennart, Jean Dellamonica, Hervé Hyvernat, Milou-Daniel Drici","doi":"10.1016/j.therap.2024.12.001","DOIUrl":"https://doi.org/10.1016/j.therap.2024.12.001","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[ISO 9001 certification: Experience of the immunology and cell therapy laboratory at Ibn Sina University Hospital, Rabat]. [ISO 9001 认证:拉巴特伊本-西纳大学医院免疫学和细胞疗法实验室的经验]。
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-04 DOI: 10.1016/j.therap.2024.11.005
Nada Saout, Ouafa Atouf, Malika Essakalli

Medical analysis laboratories play an essential role in medical diagnosis, with their results influencing up to 70% of decisions. This means that the quality of laboratory services is a key factor in the quality of medical care. However, certification and accreditation are not yet compulsory in Morocco, and only the Guide to the Good Execution of Medical Biology Analyses (GBEA) published in 2011 governs the organisation of laboratories. The Blood Transfusion and Hemovigilance Service (STSH) at the Ibn Sina University Hospital (CHUIS) in Rabat has embarked on an ISO 9001:2015 certification process, with the aim of improving its performance and satisfying its interested parties. This process, which was launched in 2018, was carried out in two main phases. The first phase consisted of complying with current regulations, while the second phase involved an evaluation based on the ISO 9001:2015 standard. In accordance with the logic of the Deming wheel, the department developed its quality policy, set its objectives, and undertook staff training and awareness activities. The processes, along with the associated risks and opportunities, have been identified and represented. The documentation system, as well as the system for reporting and handling non-conformities, has been implemented and dematerialised. Performance and activity indicators have been defined for each process. Finally, the customer feedback system has been expanded to include all interested parties, thus allowing for an evaluation of their perceptions and the identification of areas for improvement. Despite the global pandemic of COVID-19, this work has successfully integrated ISO 9001:2015 into STSH's practices, with compliance being declared by a certification body in 2022.

医学分析实验室在医学诊断中发挥着至关重要的作用,其结果影响着高达70%的决定。这意味着实验室服务的质量是医疗质量的关键因素。然而,在摩洛哥,认证和认可还不是强制性的,只有2011年出版的《良好执行医学生物学分析指南》(GBEA)管理着实验室的组织。拉巴特伊本西纳大学医院(CHUIS)的输血和血液警戒服务(STSH)已经开始了ISO 9001:2015认证过程,目的是提高其绩效并满足其相关方。这一进程于2018年启动,分两个主要阶段进行。第一阶段包括遵守现行法规,而第二阶段涉及基于ISO 9001:2015标准的评估。按照戴明轮的逻辑,部门制定了质量方针,设定了目标,并开展了员工培训和意识活动。这些过程以及相关的风险和机会都已被识别和描述。文件系统,以及报告和处理不符合的系统,已经实施和非物质化。已经为每个过程定义了性能和活动指标。最后,顾客反馈系统已扩大到包括所有有关方面,从而允许评价他们的看法和确定需要改进的领域。尽管2019冠状病毒病在全球流行,但这项工作已成功将ISO 9001:2015纳入STSH的实践,并于2022年由认证机构宣布符合要求。
{"title":"[ISO 9001 certification: Experience of the immunology and cell therapy laboratory at Ibn Sina University Hospital, Rabat].","authors":"Nada Saout, Ouafa Atouf, Malika Essakalli","doi":"10.1016/j.therap.2024.11.005","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.005","url":null,"abstract":"<p><p>Medical analysis laboratories play an essential role in medical diagnosis, with their results influencing up to 70% of decisions. This means that the quality of laboratory services is a key factor in the quality of medical care. However, certification and accreditation are not yet compulsory in Morocco, and only the Guide to the Good Execution of Medical Biology Analyses (GBEA) published in 2011 governs the organisation of laboratories. The Blood Transfusion and Hemovigilance Service (STSH) at the Ibn Sina University Hospital (CHUIS) in Rabat has embarked on an ISO 9001:2015 certification process, with the aim of improving its performance and satisfying its interested parties. This process, which was launched in 2018, was carried out in two main phases. The first phase consisted of complying with current regulations, while the second phase involved an evaluation based on the ISO 9001:2015 standard. In accordance with the logic of the Deming wheel, the department developed its quality policy, set its objectives, and undertook staff training and awareness activities. The processes, along with the associated risks and opportunities, have been identified and represented. The documentation system, as well as the system for reporting and handling non-conformities, has been implemented and dematerialised. Performance and activity indicators have been defined for each process. Finally, the customer feedback system has been expanded to include all interested parties, thus allowing for an evaluation of their perceptions and the identification of areas for improvement. Despite the global pandemic of COVID-19, this work has successfully integrated ISO 9001:2015 into STSH's practices, with compliance being declared by a certification body in 2022.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Acute cytolytic hepatitis followed by edema associated with the use of antipsychotics neuroleptics: A case report and review of the literature]. [与使用抗精神病药物抗神经抑制药相关的急性溶血性肝炎继发水肿:一例报告和文献回顾]。
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-23 DOI: 10.1016/j.therap.2024.11.004
Fatma Guermazi, Rabeb Jbir, Imen Bouaziz, Rim Atheymen, Dorra Mnif, Nourelhouda Ben Ali, Kamilia Ksouda, Khaled Zghal, Imen Baati, Jawaher Masmoudi
{"title":"[Acute cytolytic hepatitis followed by edema associated with the use of antipsychotics neuroleptics: A case report and review of the literature].","authors":"Fatma Guermazi, Rabeb Jbir, Imen Bouaziz, Rim Atheymen, Dorra Mnif, Nourelhouda Ben Ali, Kamilia Ksouda, Khaled Zghal, Imen Baati, Jawaher Masmoudi","doi":"10.1016/j.therap.2024.11.004","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.004","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxybutynin induced blindness in a child: Case report. 奥施布宁致儿童失明1例。
IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-22 DOI: 10.1016/j.therap.2024.11.003
Mouna Daldoul, Ahmed Zaiem, Yasmine Salem Mahjoubi, Ons Charfi, Ghozlane Lakhoua, Sarrah Kastalli, Riadh Daghfous, Imen Aouinti, Sihem El Aidli
{"title":"Oxybutynin induced blindness in a child: Case report.","authors":"Mouna Daldoul, Ahmed Zaiem, Yasmine Salem Mahjoubi, Ons Charfi, Ghozlane Lakhoua, Sarrah Kastalli, Riadh Daghfous, Imen Aouinti, Sihem El Aidli","doi":"10.1016/j.therap.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.003","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1